|
|
Volumn 8, Issue 3, 2007, Pages 82-
|
|
The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from rimonabant in obesity (RIO) trials
a a a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADIPONECTIN;
CANNABINOID 1 RECEPTOR ANTAGONIST;
FENFLURAMINE;
HIGH DENSITY LIPOPROTEIN;
PHENTERMINE;
PLACEBO;
RIMONABANT;
TRIACYLGLYCEROL;
ANXIETY DISORDER;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DEPRESSION;
DIABETES MELLITUS;
EPIDEMIC;
GLYCEMIC CONTROL;
HUMAN;
INTRAABDOMINAL FAT;
LIPID BLOOD LEVEL;
METABOLIC DISORDER;
NOTE;
OBESITY;
OUTCOMES RESEARCH;
RISK MANAGEMENT;
SUBCUTANEOUS FAT;
TRIACYLGLYCEROL BLOOD LEVEL;
WAIST CIRCUMFERENCE;
WEIGHT REDUCTION;
|
|
EID: 42649124022
PISSN: 10983597
EISSN: None
Source Type: Journal
DOI: 10.1016/S1098-3597(07)80031-7 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|